ClinicalTrials.gg
Not yet recruitingNCT07947160COCOONUpdated Nov 18, 2026

High-flow Nasal Oxygenation in Obese Patients During Colonoscopy: a Randomized Controlled Trial (COCOON)

An interventional study of Conventional oxygen therapy (oxygen capnography mask) and High-flow nasal oxygen therapy (Optiflow®) in Obesity (BMI>30), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Prevention

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 16 under way, 1 of them phase 3. Obesity · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
20th of 38
100 · median 110
Started
2027
the only one that year
No phase
30 of 58
9 open now
Primary completion
2028-07
later than 11 of 15 live
Registered
58th of 58
by date

Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, this one is the 20th largest by planned enrollment of the 38 interventional ones that give a count, is the only one that started in 2027, is one of 30 with no phase, reaches primary completion later than 11 of the 15 other live ones, and was the 58th registered.

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

16 of the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether high-flow oxygen therapy (HFOT) is more effective than conventional oxygen therapy (COT) in reducing episodes of intraoperative oxygen desaturation (oxygen saturation [SpO2] ≤ 90%) during colonoscopy under general anesthesia in adults with a body mass index (BMI) of 30 kg/m² or higher.

The main question it aims to answer is:

Does high-flow oxygen therapy reduce the occurrence of intraoperative oxygen desaturation compared with conventional oxygen therapy during colonoscopy under general anesthesia? Researchers will compare high-flow oxygen therapy with conventional oxygen therapy to determine whether high-flow oxygen therapy reduces the occurrence of intraoperative oxygen desaturation.

Participants will:

Be screened during their anesthesia consultation between 60 days and 48 hours before the scheduled colonoscopy.

Be randomly assigned (1:1) to receive either conventional oxygen therapy or high-flow oxygen therapy. Receive standard monitoring and 3 minutes of pre-oxygenation according to their assigned treatment group.

Undergo colonoscopy under general anesthesia while breathing spontaneously. Be monitored for oxygen desaturation during the procedure. Have ventilatory and hemodynamic data recorded during the procedure and collected immediately after the colonoscopy.

The study will include adults scheduled for a colonoscopy at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.

Read the detailed description

Prospective, multicentre, controlled, randomized, parallel-group superiority trial with a 1:1 allocation ratio, with participants blinded to the oxygen treatment received, comparing high-flow oxygen therapy (HFOT) with conventional oxygen therapy (COT) delivered through an oxygen mask. The study aims to determine whether HFOT is more effective than COT in preventing intraoperative oxygen desaturation during colonoscopy under general anesthesia in participants with a body mass index (BMI) of 30 kg/m² or higher.

Adults with a body mass index (BMI) of 30 kg/m² or higher who are scheduled to undergo a colonoscopy at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.

After written informed consent has been obtained, participants will be randomized by the study investigators to one of the two treatment groups: conventional oxygen therapy (COT); high-flow oxygen therapy (HFOT).

A computer-generated randomization list with a 1:1 allocation ratio and variable block sizes will be prepared by a statistician from the URC Paris Nord Secteur Ouest, in accordance with the sponsor's procedures. Allocation will be concealed, as the randomization list will not be accessible to the study team. The list will be directly integrated into CleanWEB™, a secure, centralized, 24- hour Internet platform, which will also be used for the electronic case report form (eCRF).

03

Conditions studied

  • Obesity (BMI>30)

Browse trials for

Keywords

  • Obesity
  • Intraoperative oxygen desaturation
  • Colonoscopy
  • General anesthesia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • (BMI) of 30 kg/m² or higher.
  • Scheduled to undergo a colonoscopy under general anesthesia with spontaneous breathing at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
  • Affiliated with a social security scheme.
  • Free, informed and written consent signed.

Exclusion criteria

Exclusion Criteria:

  • Colonoscopy in a participant at high risk of aspiration requiring orotracheal intubation, defined by at least one of the following:

    • Symptomatic or severe gastroesophageal reflux disease, notably with frequent regurgitation (≥ 2 episodes per week), mainly occurring in the supine position;
    • Hiatal hernia;
    • History of bariatric surgery (sleeve gastrectomy, gastric bypass);
    • Neurodegenerative disease requiring airway protection during colonoscopy.
  • Emergency colonoscopy.
  • Chronic respiratory failure.
  • Severe heart failure.
  • Allergy to propofol.
  • Pregnant or breastfeeding woman.
  • Adult under legal protection (guardianship or curatorship).
  • Beneficiary of State Medical Aid (Aide Médicale de l'État, AME).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Conventional oxygen therapy

    Participants assigned to the conventional oxygen therapy group will receive 100% oxygen at 6 L/min through an oxygen capnography mask during the 3-minute pre-oxygenation period and throughout the procedure. After pre-oxygenation, propofol will be administered by target-controlled intravenous infusion, with an initial target concentration of 2 µg/mL. The anesthetist may adjust the target concentration to achieve deep sedation according to American Society of Anesthesiologists (ASA) criteria. The colonoscopy will be performed while participants breathe spontaneously.

    Device: Conventional oxygen therapy (oxygen capnography mask)

  • Experimental
    High-flow oxygen therapy

    Participants assigned to the high-flow oxygen therapy group will receive 100% oxygen at 50 L/min through an Optiflow® system (Fisher \& Paykel Healthcare) during the 3-minute pre-oxygenation period and throughout the procedure. After pre-oxygenation, propofol will be administered by target-controlled intravenous infusion, with an initial target concentration of 2 µg/mL. The anesthetist may adjust the target concentration to achieve deep sedation according to American Society of Anesthesiologists (ASA) criteria. The colonoscopy will be performed while participants breathe spontaneously.

    Device: High-flow nasal oxygen therapy (Optiflow®)

Interventions

  • DeviceConventional oxygen therapy (oxygen capnography mask)

    100% oxygen delivered at a flow rate of 6 L/min through an oxygen capnography mask, during the 3-minute pre-oxygenation period and throughout the colonoscopy performed under general anesthesia (propofol target-controlled infusion) with spontaneous breathing.

    Also known as: COT, Standard oxygen therapy

  • DeviceHigh-flow nasal oxygen therapy (Optiflow®)

    100% oxygen delivered at a flow rate of 50 L/min through an Optiflow® high-flow nasal system (Fisher \& Paykel Healthcare), during the 3-minute pre-oxygenation period and throughout the colonoscopy performed under general anesthesia (propofol target-controlled infusion) with spontaneous breathing.

    Also known as: HFOT, HFNO, High-flow nasal cannula oxygen

06

What researchers measure

Primary outcomes

  1. Number of participants with at least one episode of oxygen desaturation (SpO2 ≤ 90%) during the procedure

    Oxygen desaturation is defined as a peripheral oxygen saturation (SpO2) ≤ 90%, regardless of its duration, measured by continuous pulse oximetry during the colonoscopy performed under general anesthesia.

    Time frame: From the start to the end of the procedure (Day 0)

Secondary outcomes

  1. Total number of episodes of oxygen desaturation (SpO₂ ≤ 90%) during the procedure

    Number of desaturation episodes (SpO2 ≤ 90%) per participant, determined from continuously recorded pulse oximetry data.

    Time frame: From the start to the end of the procedure (Day 0)

  2. Cumulative duration of oxygen desaturation episodes (SpO2 ≤ 90%) relative to the total duration of the procedure

    Total time (in seconds) spent with SpO2 ≤ 90%, divided by the total duration of the procedure, i.e. the fraction of procedure time spent in desaturation (between 0 and 1), determined from continuously recorded pulse oximetry data.

    Time frame: From the start to the end of the procedure (Day 0)

  3. Occurrence of an episode of hypotension, defined as systolic blood pressure (SBP) < 100 mmHg, during the procedure

    Determined from continuously recorded non-invasive blood pressure data.

    Time frame: From the start to the end of the procedure (Day 0)

  4. Occurrence of an episode of severe bradycardia, defined as heart rate < 40 beats/minute, during the procedure

    Determined from continuously recorded heart rate data.

    Time frame: From the start to the end of the procedure (Day 0)

  5. Use of orotracheal intubation during the procedure

    Collected from the medical record and reported in the eCRF.

    Time frame: From the start to the end of the procedure (Day 0)

  6. Occurrence of a cardiac arrest during the procedure

    Cardiorespiratory arrest, collected from the medical record and reported in the eCRF

    Time frame: From the start to the end of the procedure (Day 0)

07

Study locations

3 sites
  • Hôpital Beaujon, département d'anesthésie-réanimation, 100 boulevard du Général Leclerc
    Clichy, 92110, France
    • Stéphanie SIGAUT, Principal Investigator · Contact
  • Hôpital Louis Mourier, département d'anesthésie-réanimation, 178 rue des Renouillers
    Colombes, 92700, France
  • Hôpital Bichat-Claude Bernard, département d'anesthésie-réanimation, 46 rue Henri Huchard
    Paris, 75018, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jul 2028, 18 months later.

Of 3,694 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 18 months is below that.

Counting every sponsor, half of 3,858 studies reached it within 22 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jul 1, 2028
CompletionEst.
Aug 1, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947160
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jul 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Jules STERN
Contact
jules.stern@aphp.fr
+33140258080
Ines CHIBANE, +33140257961
Contact
ines.chibane@aphp.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion